Publications by authors named "G Hopfinger"
Background: Chimeric antigen receptor T (CART) cell therapy targeting the B cell specific differentiation antigen CD19 has shown clinical efficacy in a subset of relapsed/refractory (r/r) diffuse large B cell lymphoma (DLBCL) patients. Despite this heterogeneous response, blood pre-infusion biomarkers predicting responsiveness to CART cell therapy are currently understudied.
Methods: Blood cell and serum markers, along with clinical data of DLBCL patients who were scheduled for CART cell therapy were evaluated to search for biomarkers predicting CART cell responsiveness.
Article Synopsis
- Personalized medicine seeks to match specific cancer treatments to individual patients based on their tumor characteristics, but current methods only assist less than 10% of patients.
- A new approach, called single-cell functional precision medicine (scFPM), was tested on 143 patients with aggressive hematologic cancers, where 39% received treatments guided by scFPM results.
- Results showed that 54% of patients treated according to scFPM experienced improved progression-free survival, with some achieving exceptional responses lasting three times longer than typical, indicating the method's clinical feasibility and effectiveness.
T-cell prolymphocytic leukemia (T-PLL) is a poor-prognostic neoplasm. Differentiation stage and immune-effector functions of the underlying tumor cell are insufficiently characterized. Constitutive activation of the T-cell leukemia 1A (TCL1A) oncogene distinguishes the (pre)leukemic cell from regular postthymic T cells.
View Article and Find Full Text PDF